Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2017

View Archived Issues

Atara Biotherapeutics starts phase I study of allogeneic ATA-188 in multiple sclerosis

[68Ga]NODAGA-exendin-4 used to image beta cells after Roux-en-Y gastric bypass

Novel orally bioavailable BAX activator shows promising antitumor activity in leukemia xenografts

Novel glucosylceramidase activators presented by Lysosomal Therapeutics

Osimertinib-savolitinib combination shows promise in EGFR-mutant NSCLC

Researchers describe a novel athyroid mouse model

FDA approves Shingrix

Spero Therapeutics commences clinical testing of SPR-994

FDA approves Simponi Aria for psoriatic arthritis and ankylosing spondylitis

FDA grants new breakthrough therapy designation to Tafinlar + Mekinist in melanoma

VBL Therapeutics' VB-111 granted orphan medicinal product status in E.U.

FDA grants orphan drug designation to Cx-601 for fistulizing Crohn's disease

Activity seen with etirinotecan pegol in phase II small-cell lung cancer trial

New susceptibility genes revealed for Kawasaki disease

FDA issues complete response letter for Xyosted

FDA approves Bydureon BCise

Ergomed reports phase II topline results for first-in-class hemostat PeproStat

Japanese NDA filing for Lynparza for germline BRCA-mutated, HER2-negative metastatic breast cancer

Population Council initiates phase I study of griffithsin gel for HIV prevention

Immunomedics initiates phase III study of sacituzumab govitecan for triple-negative breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...